Product
IMU-838
Aliases
IM90838, IMU-838 tablets, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium (2 other aliases)
6 clinical trials
4 indications
Indication
ulcerative colitisIndication
Multiple SclerosisIndication
Relapsing-RemittingIndication
COVID-19Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative ColitisStatus: Terminated, Estimated PCD: 2022-11-16
Clinical trial
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisStatus: Active (not recruiting), Estimated PCD: 2025-01-07
Clinical trial
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19Status: Completed, Estimated PCD: 2022-05-20
Clinical trial
Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)Status: Active (not recruiting), Estimated PCD: 2020-04-24